Browse studies

Find your next paid study

27,292 recruiting studies available now

Phase 2 Randomized, Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Icovamenib in Participants With Type 2 Diabetes Not Achieving Glycemic Targets Despite GLP-1-Based Therapy

This is a phase 2 randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes (T2D)…

Type 2 Diabetes

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Biomea Fusion Inc.NCT07502508

Observational

Quantifying Motor Network Dynamics to Predict and Enhance Outcomes in Pediatric Dystonia

The goal of this study is to understand the development and progression of childhood dystonia, a movement disorder, in children. The main questions it aims to …

DystoniaPediatricDeep Brain Stimulation+1 more

Estimated

~$10 – $675

Actual pay is set by the research site.

Children's Hospital Medical Center, CincinnatiNCT07325175

Observational

Comparative Efficacy, Safety, and Efficiency of SYSTEM 1 Versus SYSTEM 2 Pulse Field Ablation Systems for Atrial Fibrillation Ablation Randomized Controlled Trial

This study randomizes patients undergoing PFA for A Fib to one of two standard care PFA systems. The patient will have an ICM placed to continuously monitor th…

AF - Atrial Fibrillation

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)NCT07883629

Phase 2

Bexmarilimab Plus Azacitidine in a Randomized, Double-blind, Placebo-controlled Phase IIb Trial in Treatment-naïve Higher-risk Myelodysplastic Syndromes (HR-MDS)

This Phase IIb study (BEXERA) will evaluate the safety and efficacy of bexmarilimab (FP-1305), an antibody targeting Clever-1, given in combination with azacit…

Higher Risk Myelodysplastic Syndromes

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Faron Pharmaceuticals LtdNCT07672769

Phase 1

A Phase 1/1b Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 436 as Monotherapy and in Combination With Other Therapies in Participants With Microsatellite Instability-high (MSI-H)/Mismatch Repair Deficient (dMMR) Solid Tumors

The primary objectives of this trial are to evaluate the safety profile of AMG 436 and to determine the maximum tolerated dose (MTD) and/or the recommended dos…

Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)

Estimated

~$150 – $4,500

Actual pay is set by the research site.

AmgenNCT07403721

Observational

Fluid Guided Heart Failure Treatment

FIGHT-HF is an exploratory non-randomized open-label study evaluating a heart failure management intervention. The goal of this pilot is to assess the perform…

Heart Failure

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Bodyport Inc.NCT07205120

Phase 1

Pilot Trial of Olutasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplantation in Patients Carrying IDH1 Mutation With AML, MDS, or CMML Disease

This phase I trial tests the safety, side effects, and effectiveness of olutasidenib in preventing the return of disease (relapse) in patients who have undergo…

Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome

Estimated

~$150 – $3,000

Actual pay is set by the research site.

City of Hope Medical CenterNCT06543381

Phase 2

A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants With Early Alzheimer's Disease

Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a typ…

Early Alzheimer's Disease

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Merck Sharp & Dohme LLCNCT07033494

Observational

Neuromuscular Electrical Stimulation: A Novel Treatment for Improving Metabolism

Once written consent is obtained, the participant will be provided with an accelerometer to be worn for 7 days to assess current physical activity levels. Subj…

Insulin Resistance

Estimated

~$10 – $750

Actual pay is set by the research site.

University of Texas, El PasoNCT06722391

Phase 3

A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination With Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors Are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-Positive

Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal jun…

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Phase 2

Study of Therapeutic Plasma Exchange, Rituximab, and Intravenous Immunoglobulin for Progressive Idiopathic Pulmonary Fibrosis (STRIVE II)

This Phase IIb trial will compare effectiveness and safety of a multi-component autoantibody reduction therapy (AART), consisting of therapeutic plasma exchang…

Idiopathic Pulmonary Fibrosis

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of Alabama at BirminghamNCT07674745

Phase 1

A Phase 1/2 Study of the Menin Inhibitor Revumenib With the CELMod Mezigdomide in Relapsed/Refractory KMT2A-rearanged, NPM1-mutant, and NUP98-rearranged Acute Leukemias

The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-…

LeukemiaAcute LeukemiaRelapse Leukemia+5 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT07356154